SAG
CRNX

SageView Advisory Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

SageView Advisory Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-110
Closed -$5.12K – 996
2025
Q4 		$5.12K Buy
+110
New +$4.9K ﹤0.01% 1962

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

SageView Advisory Group's CRNX Position: Q1 2026 in Review

SageView Advisory Group sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 110 shares — an estimated $5.12K sold.

SageView Advisory Group first reported a position in CRNX in Q4 2025 and held it in 1 quarter. The position peaked at $5.12K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • SageView Advisory Group reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 110 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $5.12K.
  • SageView Advisory Group first reported a position in Crinetics Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Crinetics Pharmaceuticals position peaked at $5.12K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.